3,032
Participants
Start Date
September 30, 2015
Primary Completion Date
July 31, 2021
Study Completion Date
August 31, 2021
Vaccination with ACAM2000
In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
Bio Products Laboratory Ltd (plasma vendor of Emergent BioSolutions), Winnipeg
Lead Sponsor
Emergent BioSolutions
INDUSTRY